Loomis, Sayles & Company
AKRO

Loomis, Sayles & Company’s Akero Therapeutics AKRO Stock Holding History

Loomis, Sayles & Company’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-527,175
Closed -$25M – 699
2025
Q3 		$25M Sell
527,175
-13,613
-3% -$659K 0.03% 205
2025
Q2 		$28.9M Buy
540,788
+51,850
+11% +$2.36M 0.04% 181
2025
Q1 		$19.8M Buy
+488,938
New +$20.7M 0.03% 237

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Loomis, Sayles & Company's AKRO Position: Q4 2025 in Review

Loomis, Sayles & Company sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 527,175 shares — an estimated $25M sold.

Loomis, Sayles & Company first reported a position in AKRO in Q1 2025 and held it in 3 quarters. The position peaked at $28.9M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Loomis, Sayles & Company reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Loomis, Sayles & Company sold 527,175 Akero Therapeutics shares in Q4 2025, an estimated $25M.
  • Loomis, Sayles & Company first reported a position in Akero Therapeutics in Q1 2025 and held it in 3 quarters.
  • Loomis, Sayles & Company's Akero Therapeutics position peaked at $28.9M in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Loomis, Sayles & Company's 13F filing for Q4 2025, filed 12 Feb 2026.